Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from clopidogrel to prasugrel in intermediate-to-high risk NSTE-ACS patients undergoing early invasive management
2011-005114-11Phase 3Active
- Sponsor
- Azienda USL di Forlì
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prasugrel and clopidogrel in acute coronary syndrome (ACS) (4 arms), sponsored by Azienda USL di Forlì. Primary endpoint: Change in residual platelet reactivity index by VASP at 4 hours. Started Dec 2011; status: active.
02
Drugs
prasugrelclopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2011-005114-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005114-11.